Tevogen Bio Holdings Inc.
TVGNNASDAQHealthcareBiotechnology
Latest quote
$6.65
+$0.38 · +5.97%
TVGN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
60
Fair Value
Momentum
18
Strong Down
Sentiment
51
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Ryan H. Saadi
- Listed since
- Jan 5, 2022
- Employees
- 18
Market position
- Volume
- 13.04K
- 0.56× average
- Average volume
- 23.41K
- Average daily volume
- Market cap
- 28.11M USD
- Beta
- 0.2
- Market reference 1
Earnings
- Latest fiscal-year EPS
- -8.08
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 6, 2026 | 1:50 | — | — |
Effective Mar 6, 2026
1:50
TVGN peers
Continue in GoAI
Research TVGNresearch.disclaimer